ID
29846
Beschrijving
https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome
Link
https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs
Trefwoorden
Versies (1)
- 24-04-18 24-04-18 - Halim Ugurlu
Houder van rechten
GSK
Geüploaded op
24 april 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
GSK Study ID 104864-201 Inclusion-Exclusion Criteria and Telephone Randomisation
Inclusion-Exclusion Criteria and Telephone Randomisation
- StudyEvent: ODM
Beschrijving
Inclusion Criteria-Do not admit the patient to this study if any "No" box has been marked
Alias
- UMLS CUI-1
- C1512693
Beschrijving
Written informed consent
Datatype
boolean
Alias
- UMLS CUI [1]
- C0021430
Beschrijving
Age
Datatype
boolean
Alias
- UMLS CUI [1]
- C0001779
Beschrijving
a)Diagnosis of myelodysplastic syndrome, subcategories of refractory anemia with excess of blasts, INT 2 or high risk (RAEB) as defined by Greenberg, et al, [4] (see protocol Appendix L), or refractory anemia with excess of blasts in transformation (RAEB-t) OR b)Diagnosis of AML which has evolved from a preceding phase of MDS defined as the presence of antecedent hematologic disorder existing for at least the past three months, AML and/or poor prognosis cytogenetics.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0011900
- UMLS CUI [1,2]
- C0023467
- UMLS CUI [2,1]
- C0011900
- UMLS CUI [2,2]
- C3463824
Beschrijving
Performance status <= 2 (Zubrod-ECOG-WHO cale, protocol Appendix C) and life expectancy =>6 weeks.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1520224
- UMLS CUI [1,2]
- C0023671
Beschrijving
Patients must not have received prior chemotherapy except low-dose ara-C, hydroxyurea, or intrathecal methotrexate for MDS or AML.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1514457
- UMLS CUI [1,2]
- C0332300
- UMLS CUI [1,3]
- C0010711
- UMLS CUI [1,4]
- C1707814
- UMLS CUI [1,5]
- C0025677
- UMLS CUI [1,6]
- C0677897
Beschrijving
Recovery from all toxicities since last chemotherapy and/or biologic therapy, unless specific conditions discussed with medical monitor.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0013221
- UMLS CUI [1,2]
- C2004454
Beschrijving
Patients with previous malignancies in CR for one year or greater.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C2735088
- UMLS CUI [1,2]
- C0006826
Beschrijving
Patients must not be candidates for curative allogenic bone marrow transplant at the time of treatment, although it is recognized they may become candidates at a future time (i.e., a matched donor is found).
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0030705
- UMLS CUI [1,2]
- C1548788
- UMLS CUI [1,3]
- C0149615
Beschrijving
Current laboratory values within the limits listed below unless agreed upon by the principal investigator and the medical monitor: - creatinine <= 1.5 mg/dL (133 micromol/l) - serum bilirubin <= 2.0 mg/dL (34 micromol/l) SGOT/SGPT <= 2 times the upper limit of normal
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0022877
- UMLS CUI [1,2]
- C0042295
Beschrijving
Patients must have a left ventricular ejection fraction (LVEF) of at least 50%
Datatype
boolean
Alias
- UMLS CUI [1]
- C0428772
Beschrijving
Exclusion Criteria-Do not admit the patient to this study if any "Yes" box has been marked
Alias
- UMLS CUI-1
- C0680251
Beschrijving
Patients who are eligible for curative allogenic bone marrow transplant without additional treatment.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0149615
- UMLS CUI [1,2]
- C0013893
Beschrijving
Patients with chromosomal abnormalities of t(15;17), t(8;21), or inv(16)
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0008625
- UMLS CUI [1,2]
- C2348235
Beschrijving
Patients with CMML.
Datatype
boolean
Alias
- UMLS CUI [1]
- C0023480
Beschrijving
Less than 3 weeks since major surgery, except for placement of central line.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0679637
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0040223
Beschrijving
Concomitant malignancies with the exception of curatively treated basal cell carcinoma of the skin, carcinoma in situ of the cervix and previous malignancies in CR for less than one year.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0006826
- UMLS CUI [1,2]
- C0332196
- UMLS CUI [1,3]
- C0007114
- UMLS CUI [1,4]
- C2216722
- UMLS CUI [1,5]
- C0242793
Beschrijving
Concurrent severe medical problems unrelated to the malignancy which would significantly limit the full compliance with the study or expose the patient to extreme risk.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0009488
- UMLS CUI [1,2]
- C0205082
Beschrijving
Uncontrolled or severe cardiovascular disease including recent (< 3 months) myocardial infarction or congestive heart failure.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0007222
- UMLS CUI [1,2]
- C0205318
- UMLS CUI [1,3]
- C0205082
Beschrijving
Active infection
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C3714514
- UMLS CUI [1,2]
- C0205177
Beschrijving
Patients who have a history of (+) HIV.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0019693
- UMLS CUI [1,2]
- C0262926
Beschrijving
Patients who have (+) PPD with abnormal CXR
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0032739
- UMLS CUI [1,2]
- C2041426
- UMLS CUI [1,3]
- C0205161
Beschrijving
Females of child-bearing potential, not practicing adequate contraception. Females of child-bearing potential, premenopausal (less than 60 years of age), or not surgically sterilized must use effective contraception by barrier method contraception, an interuterine device (IUD) or use of birth control pill for 3 months prior to entry into the study and agree to continue to use it during the study and for at least 4 weeks after the end of study drug administration.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1960468
- UMLS CUI [1,2]
- C0700589
Beschrijving
Pregnancy or lactation.
Datatype
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Beschrijving
Use of an investigational drug (including a cytotoxic drug) within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0013230
- UMLS CUI [1,2]
- C0040223
Beschrijving
Concurrent use of other chemotherapy
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0003392
- UMLS CUI [1,2]
- C4060806
Beschrijving
Any chemotherapy with topotecan or idarubicin
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C3665472
- UMLS CUI [1,2]
- C0146224
- UMLS CUI [2]
- C0020789
Beschrijving
History of hypersensitivity to compounds chemically related to topotecan, ara-C, idarubicin or G-CSF.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0146224
- UMLS CUI [1,3]
- C0733521
- UMLS CUI [1,4]
- C0020789
- UMLS CUI [1,5]
- C0079459
Beschrijving
Patient known to be refractory to "platelet transfusions."
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0086818
- UMLS CUI [1,2]
- C0205269
Beschrijving
Telephone Randomisation
Alias
- UMLS CUI-1
- C0039457
- UMLS CUI-2
- C0034656
Beschrijving
If Yes to Telephone Randomisation
Alias
- UMLS CUI-1
- C0039457
- UMLS CUI-2
- C0034656
Similar models
Inclusion-Exclusion Criteria and Telephone Randomisation
- StudyEvent: ODM
C0023467 (UMLS CUI [1,2])
C0011900 (UMLS CUI [2,1])
C3463824 (UMLS CUI [2,2])
C0023671 (UMLS CUI [1,2])
C0332300 (UMLS CUI [1,2])
C0010711 (UMLS CUI [1,3])
C1707814 (UMLS CUI [1,4])
C0025677 (UMLS CUI [1,5])
C0677897 (UMLS CUI [1,6])
C2004454 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,2])
C1548788 (UMLS CUI [1,2])
C0149615 (UMLS CUI [1,3])
C0042295 (UMLS CUI [1,2])
C0013893 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
C0332196 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
C2216722 (UMLS CUI [1,4])
C0242793 (UMLS CUI [1,5])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C0205177 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,2])
C2041426 (UMLS CUI [1,2])
C0205161 (UMLS CUI [1,3])
C0700589 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0040223 (UMLS CUI [1,2])
C4060806 (UMLS CUI [1,2])
C0146224 (UMLS CUI [1,2])
C0020789 (UMLS CUI [2])
C0146224 (UMLS CUI [1,2])
C0733521 (UMLS CUI [1,3])
C0020789 (UMLS CUI [1,4])
C0079459 (UMLS CUI [1,5])
C0205269 (UMLS CUI [1,2])
C0034656 (UMLS CUI-2)
C0034656 (UMLS CUI [1,2])
C0034656 (UMLS CUI-2)
Geen commentaren